Advani R, Warnke R, Rosenberg S
Stanford University School of Medicine, Division of Oncology, CA, USA.
Ann Oncol. 1999 Oct;10(10):1207-9. doi: 10.1023/a:1008366721816.
Castleman's disease or angiofollicular lymph node hyperplasia is a rare entity with a localized/unicentric or a generalized/multicentric presentation. While surgery is curable for most localized presentations, there is limited information regarding the optimal management of the multicentric type. The latter type is associated with a poor prognoses and can be associated with the development of lymphoma and infections.
In this report we describe a case of multicentric Castleman's disease who failed steroids and chemotherapy and developed a follicular mixed lymphoma. He was treated with high-dose chemotherapy with autologous stem-cell support and remains disease at four years of follow-up.
A long-term durable remission may be possible with high dose chemotherapy with stem-cell support. This treatment modality should be considered an option in the management of multicentric Castleman's disease.
Castleman病或血管滤泡性淋巴结增生是一种罕见疾病，有局限性/单中心型或全身性/多中心型表现。虽然手术可治愈大多数局限性病例，但关于多中心型的最佳治疗方法的信息有限。后一种类型预后较差，可能与淋巴瘤和感染的发生有关。
在本报告中，我们描述了一例多中心Castleman病患者，该患者对类固醇和化疗无效，并发展为滤泡性混合淋巴瘤。他接受了高剂量化疗并自体干细胞支持治疗，随访四年时仍无疾病进展。
高剂量化疗联合干细胞支持可能实现长期持久缓解。这种治疗方式应被视为多中心Castleman病治疗的一种选择。
